TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30697914
Drug: Routine physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine physiotherapy with cupping therapy
Study: 26448178
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg once daily for 4 weeks on treatment; 2 weeks off)
Study: 24271647
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg) for 14 days
Study: 19751559
Drug: Preemptive anti-Candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive anti-Candida treatment based on corrected colonization index (CCI) when CCI >= 0.4 and evidence of sepsis; treatment not given when CCI < 0.4, but given if the patient's condition worsened.
Study: 17225720
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% fluticasone propionate
Study: 12003253
Drug: Chronic low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chronic low-dose transdermal nicotine
Study: 26859064
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200mg once daily for six days
Study: 26859064
Drug: Linezolid 600mg
Normalized name: LINEZOLID 600MG TAB
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 600mg twice daily for 10 days
Study: 22110122
Drug: DAS-steered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS-steered treatment in ACPA-positive patients
Study: 22110122
Drug: DAS-steered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS-steered treatment in ACPA-negative patients
Study: 22110122
Drug: Initial monotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial monotherapy in ACPA-positive patients
Study: 20969662
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with intradermal cross-linked hyaluronic acid and onabotulinumtoxinA
Study: 20969662
Drug: Cross-linked hyaluronic
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-linked hyaluronic acid monotherapy
Study: 17624209
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.3 mg) plus PCA
Study: 16360446
Drug: COX‐2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitor (rofecoxib 25 mg/day)
Study: 16360446
Drug: No COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: No COX‐2 inhibitor
Study: 12502178
Drug: Choline ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline ingestion (50 mg/kg body weight)
Study: 21823552
Drug: MoxDuo 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoxDuo 12 mg/8 mg
Study: 21823552
Drug: MoxDuo 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: MoxDuo 6 mg/4 mg
Study: 19210951
Drug: Aripiprazole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (2.5 to 15 mg/day, mean dose 9.0 mg/day) for 12 weeks
Study: 19210951
Drug: Continuation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation treatment with aripiprazole
Study: 14726726
Drug: Methylphenidate 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.25 mg/kg body weight
Study: 14726726
Drug: Methylphenidate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.5 mg/kg body weight
Study: 11739299
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg/d, n=18)
Study: 11739299
Drug: Naproxen (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (750 mg/d, n=17)
Study: 2656340
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (10 micrograms) of SMS 201-995
Study: 2656340
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (50 micrograms) of SMS 201-995
Study: 27818309
Drug: Telephonic support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephonic support for loop diuretic adherence monitoring
Study: 23972529
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone 30 minutes before a memory encoding task
Study: 23972529
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hydrocortisone 210 minutes before a memory encoding task
Study: 10766888
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg) with standard Sinemet
Study: 10766888
Drug: Entacapone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entacapone (200 mg) with Sinemet CR
Study: 29650807
Drug: HCT care
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCT care coordination (CC) intervention
Study: 26290103
Drug: 30 g/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/120 kcal whey protein
Study: 26290103
Drug: 70 g/280
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 g/280 kcal whey protein
Study: 26290103
Drug: Flavored water
Normalized name: FLAVOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored water control drink (0 g whey protein)
Study: 23287635
Drug: Progesterone injection
Normalized name: Progesterone Injection
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone injection plus oral E2 supplementation (Group A)
Study: 23287635
Drug: Progesterone injection
Normalized name: Progesterone Injection
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone injection alone (Group B)
Study: 20568427
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with cupping and western medicine (group A)
Study: 20568427
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (group C)
Study: 16987363
Drug: E120 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: E120 group (120 mg etoricoxib)
Study: 16987363
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + P group (120 mg etoricoxib + 1 g paracetamol)
Study: 14501603
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (Premarin, 1.25 mg)
Study: 11073759
Drug: Azithromycin 600
Normalized name: azithromycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 600 mg every day combined with ethambutol
Study: 11073759
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice a day combined with ethambutol
Study: 1286738
Drug: ViviScal (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: ViviScal (two tablets once daily for 6 months)
Study: 1286738
Drug: Fish extract
Normalized name: channel catfish extract 50 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish extract (two tablets once daily for 6 months)
Study: 28724200
Drug: Memantine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 30 mg twice daily for 7 days
Study: 23169607
Drug: ACE-031 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-031 (3 mg/kg s.c.)
Study: 18435331
Drug: Infusion removal
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion removal first (Group 1, 30 eyes)
Study: 18435331
Drug: Infusion removal
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion removal after another cannula (Group 2, 32 eyes)
Study: 18435331
Drug: Infusion removal
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion removal last (Group 3, 33 eyes)
Study: 10806605
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (Azmacort HFA 225 mcg Inhalation Aerosol)
Study: 10806605
Drug: Budesonide (Pulmicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (Pulmicort Turbuhaler 200 mcg)
Study: 9015909
Drug: Physiological saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline, 1 ml/day intramuscularly for 4 weeks
Study: 6638669
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (4 doses of 30 g each, administered every 2 hours)
Study: 6638669
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (4 doses of 30 g every 2 hours) in a patient with initial serum theophylline concentration of 31.0 micrograms/ml and signs of toxicity
Study: 24530600
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ASP9831
Study: 24530600
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ASP9831
Study: 15866088
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/day) plus atorvastatin (20 mg/day)
Study: 10340182
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors treatment initiated and monitored by primary care physicians
Study: 10340182
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors treatment
Study: 2192570
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol infusion with analgesia from bolus doses of papaveretum
Study: 2192570
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of papaveretum supplemented by bolus doses of midazolam
Study: 395771
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate isomers (4.5 g per day for 64 months)
Study: 395771
Drug: Chondroitin polysulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin polysulfate (4.5 g per day for 64 months)
Study: 395771
Drug: Chondroitin 4-sulfate
Normalized name: chondroitin 4-sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin 4-sulfate and/or chondroitin 6-sulfate (4.5 g per day for 64 months)
Study: 21254788
Drug: Aripiprazole as
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole as adjunctive therapy to antidepressants
Study: 18833207
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection into incisive papilla (Control)
Study: 11882746
Drug: nizatidine 75
Normalized name: nizatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 75 mg twice daily
Study: 11882746
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet twice daily
Study: 10225502
Drug: Standard Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Eye Movement Desensitization and Reprocessing (EMDR) treatment
Study: 10225502
Drug: Similar treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar treatment without the explicit cognitive elements found in EMDR
Study: 2676530
Drug: Fentanyl and
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl and two-stage infusion of propofol in a subanaesthetic dose
Study: 1001000
Drug: Acebutolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (100 mg to 1200 mg/day in divided doses)
Study: 29173690
Drug: Omega-3 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 group (daily intake of 1080mg EPA + 200mg DHA for 12 weeks)
Study: 26367143
Drug: Manipulation under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manipulation under anaesthesia (MUA) with additional subacromial injection of triamcinolone and bupivacain
Study: 23201448
Drug: FraxiPure™ (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: FraxiPure™ (1000 mg daily for 90 days)
Study: 21615691
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g and Ketorolac 20 mg combination
Study: 12637702
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 to 300 mg/d)
Study: 12637702
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and Clopidogrel (combined therapy)
Study: 10818061
Drug: Second-line drugs
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line drugs (Atenolol or Enalapril)
Study: 10818061
Drug: Isolated systolic
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated systolic hypertension treatment
Study: 1522663
Drug: Single prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single prophylactic injection of gentamicin
Study: 25312396
Drug: Nintedanib (BIBF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (BIBF 1120) at a dose of 200mg twice daily
Study: 20970572
Drug: 1 μg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/d paricalcitol (n=25)
Study: 18039918
Drug: Resiquimod 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resiquimod 0.01% gel applied two times per week for 3 weeks
Study: 12021625
Drug: Thiopurine metabolism
Normalized name: thiotaurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopurine metabolism
Study: 10071518
Drug: chlorpheniramine 8
Normalized name: CODEINE 54.3/CHLORPHENIRAMINE 8MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpheniramine 8 mg
Study: 10071518
Drug: All H1-receptor
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All H1-receptor antagonists
Study: 1705193
Drug: Combined contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined contraceptive pills containing desogestrel and gestodene
Study: 6789354
Drug: Flurazepam 26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam 26 mg
Study: 6789354
Drug: Flurazepam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurazepam (all doses)
Study: 25622803
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants placed with osteotome sinus floor elevation (OSFE) without grafting (test group)
Study: 25622803
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants placed with osteotome sinus floor elevation (OSFE) with grafting (control group)
Study: 17634459
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks through week 24
Study: 215096
Drug: Morphine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (120 mg doses)
Study: 26341987
Drug: AZD5069 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5069 80 mg orally twice daily for 28 days
Study: 23561868
Drug: Pilates exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates exercise program (twice a week for one year)
Study: 14734920
Drug: Injection rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection rate of 0.5 mL/s
Study: 14734920
Drug: Injection volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection volume (2, 10, 20 mL)
Study: 14734920
Drug: Flow rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow rates of 1 to 2 mL/s with a minimum of 20 mL gadolinium dimeglumine
Study: 11743482
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gluconate/61% ethanol antiseptic hand preparation
Study: 9162612
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum bread (7.6 g guar per meal)
Study: 9162612
Drug: Control (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (75 g carbohydrate breakfast meals of control bread)
Study: 6839561
Drug: Tizolemide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizolemide (50 mg i.v.)
Study: 31347916
Drug: Knowledge/tools and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge/tools and solutions for improving experimental design
Study: 27614276
Drug: Equestrian therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equestrian therapy (24 biweekly sessions over 3 months)
Study: 22192423
Drug: Split-dose picosulfate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose picosulfate, magnesium oxide, and citric acid solution (1 sachet at 7:00 pm and another sachet 4 hours before colonoscopy)
Study: 22192423
Drug: Traditional dosing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional dosing regimen (1 sachet at 5:00 pm and 10:00 pm the night before colonoscopy)
Study: 17592349
Drug: Thiopentone 3
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 3 mg/kg
Study: 12467851
Drug: Parametric method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parametric method of estimating Doppler ultrasound umbilical maximal flow waveform envelope; No specific dosage or duration mentioned.
Study: 12467851
Drug: Modification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modification of the estimation procedure; No specific dosage or duration mentioned.
Study: 23263559
Drug: Tacrolimus once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus once-daily regimen
Study: 23263559
Drug: Tacrolimus twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus twice-daily regimen
Study: 21719530
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin embedded in a phosphorylcholine matrix (XPC group)
Study: 19127975
Drug: Free primary
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free primary health care (prepayment scheme allowing free primary care including drugs)
Study: 11423055
Drug: Dobutamine (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (standard therapy)
Study: 9290362
Drug: Hyaluronan ophthalmic
Normalized name: hyaluronate Ophthalmic Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan ophthalmic solution (0.1% hyaluronic acid), instilled five times a day to the right eye
Study: 9290362
Drug: Artificial tear
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tear solutions (control group)
Study: 7975402
Drug: Anti-arteriosclerosis diet
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-arteriosclerosis diet containing 20 g of ichthyenic oil
Study: 2890806
Drug: DL‐dihydroxyphenylserine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL‐dihydroxyphenylserine 600 mg
Study: 16644430
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) stress echocardiography (peak infusion 10 microg/kg/min)
Study: 16644430
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) stress echocardiography
Study: 12676043
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for migraine/headaches
Study: 12676043
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for nausea/vomiting
Study: 10653203
Drug: Abecarnil (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil (12 mg, three times daily)
Study: 10653203
Drug: Diazepam (22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (22 mg, three times daily)
Study: 6134827
Drug: Monthly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sessions
Study: 27112723
Drug: Immediate loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate loading of 2 unsplinted implants
Study: 27112723
Drug: Unloaded implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unloaded implants (control)
Study: 20522536
Drug: FG‐3019 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG‐3019 (3 mg/kg)
Study: 20522536
Drug: FG‐3019 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG‐3019 (10 mg/kg)
Study: 16906395
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb) 360 mg/day plus haloperidol 0.25 mg/kg/day
Study: 16906395
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus haloperidol 0.25 mg/kg/day
Study: 10971385
Drug: Amifostine (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (740 mg/m2)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with egg (first dose 500 mg or less)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with milk (first dose 500 mg or less)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with soy (first dose 500 mg or less)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with wheat (first dose 500 mg or less)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with peanut (first dose 500 mg or less)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with fish (first dose 500 mg or less)